WHAT PEOPLE ACTUALLY USE, WHAT THE EVIDENCE SHOWS, AND WHAT THE FORUM HAS LEARNED
The Peptide Consensus takes the most-read peptide threads on ExcelMale and checks them against the published research. Each compound is rated on a seven-tier evidence scale, from FDA-approved to lab-dish only, with the studies named and the risks spelled out.
The full book, 201 pages in color, with a reference list at the end of every chapter so you can check the evidence yourself.
Instant download. 100% refund within 15 days.
WHAT GETS SAID ONLINE
Most peptides sold today have never completed a human trial. BPC-157's one registered trial, posted in 2015, never reported results. That doesn't mean it fails. It means the claims rest on animal data and anecdote.
The book says where the community has learned something the literature confirms, and where it believes something the literature doesn't support.
HOW IT'S BUILT
The most-discussed peptides each get a full write-up: what the compound is, how it works, what the clinical evidence shows, how people report using it, what goes wrong, and what the men who ran it said.
WHAT'S INSIDE
Peptides are grouped by what people use them for. Safety and sourcing come first.
FOUNDATIONS
What a certificate of analysis does and doesn't prove, why purity isn't the same as injectable safety, and what lab testing of gray-market products has found.
HANDLING
Why instructions must be product-specific, with a worked dosing-math example and sterility basics.
GROWTH HORMONE
Ipamorelin, CJC-1295, MK-677, sermorelin and tesamorelin, with side effects and the bloodwork to monitor.
REPAIR
BPC-157, TB-500 and GHK-Cu, and the honest question: did it work, or did the injury heal anyway?
FAT LOSS
Semaglutide, tirzepatide and retatrutide, the microdosing trend, and the older fat-loss peptides.
SEXUAL FUNCTION
PT-141 and Melanotan II, and how PT-141 compares with Trimix.
BRAIN AND AGING
Semax, Selank, DSIP, Epitalon, SS-31 and MOTS-c, plus fertility, hormonal support and muscle-growth peptides.
REGULATION
Where the FDA compounding review stands for each compound, current as of November 10, 2026.
Only a few of the compounds in this book carry FDA approval for any human use. Most are experimental, sold for research purposes, or used off-label. Every dose in the book is reported as it appears in the literature or as members described it. A reported dose is not a recommended dose. Talk to a licensed clinician before you start, stop or change anything.
Not yet. The color PDF is available here first.
Yes. Tables, figures and the evidence-tier graphics are in color. It reads best on a tablet or a computer.
No. It reports what the research shows and what community members said they did. Those reports are not protocols or recommendations. Decisions about treatment belong with you and a licensed clinician.
It is current as of November 10, 2026, including the July 2026 FDA compounding committee votes. Rules change, so check the current status before relying on it.
Yes. You get 100% of your money back if you ask within 15 days of purchase. Write to milestonespublishing@gmail.com.